Society of Thoracic Surgeons Score Variance Results in Risk Reclassification of Patients Undergoing Transcatheter Aortic Valve Replacement
The Society of Thoracic Surgeons (STS) score is the cornerstone of risk assessment for patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) in the United States. The current STS score model was implemented in 2008, and the coefficients are reestimated every year using the last 3-year study sample in the STS database.
1 Since 2007, high-risk patients have increasingly undergone TAVR, and advances in surgical technique, anesthesia, and critical care have led to improved surgical aortic valve replacement outcomes. Consequently, the STS database study sample has changed considerably. To evaluate the effect of these changes, we compared the STS scores of 177 consecutive patients undergoing TAVR in 2008/2009 in a tertiary referral hospital in the United States with their recalculated STS scores in 2015, using the updated online calculator.
Methods | The study was approved by the local institutional review board and in compliance with its regulation. Categorical variables are presented as numbers (percentages), and continuous variables are presented as mean (SD) values. (Figure 2 ). Forty percent of patients would not change classification. Mortality at 30 days and at 1 year was 11.9% and 27.1%, respectively.
Discussion | Certainly, risk assessment is influenced by additional factors, such as frailty, pulmonary hypertension, or liver disease, that we did not account for in this study. Nonetheless, the STS score remains the starting point for risk determination for all patients undergoing TAVR in the United States. Our that, in the future, surgical aortic valve replacement rarely will be performed for patients with STS scores greater than 4%. Therefore, the use of any risk score based on historic outcomes of patients undergoing aortic valve replacement will become obsolete for evaluation of patients undergoing TAVR. This raises the important question of whether indications for use for TAVR devices in the United States should reflect STS score riskdefined patient populations. Possibly a better approach would be to allow the heart team to determine optimal treatment strategy for individual patients regardless of risk score.
Conclusions | In summary, changes to the STS score algorithm over time can result in significant reduction in STS scores for patients undergoing TAVR. This observation has important implications for the conduct and interpretation of contemporary clinical trials and device indications for use because there may be considerable unrecognized overlap in risk-defined patient populations. New risk stratification scores are warranted based on outcomes of patients undergoing TAVR. 
Invited Commentary

Use of Society of Thoracic Surgeons Risk Models in the Assessment of Patients Who Underwent a Transcatheter Aortic Valve Replacement
The use of statistical risk models has become an integral part of cardiovascular medicine. Risk assessment for transcatheter aortic valve replacement (TAVR) is particularly challenging because of the need to predict risk for surgical aortic valve replacement as well as the risk of the TAVR procedure itself.
In the United States, Society of Thoracic Surgeons (STS) risk models are typically used to estimate surgical aortic valve replacement risk to categorize TAVR candidates into low-, intermediate-, or high-risk groups. These STS models are fully disclosed in the literature and provided to all STS database participants, thereby making them readily available for widespread use.
1 As pointed out by Rogers et al, 2 the models must be used carefully, with full recognition of their designed features. Temporal changes in the patient population and procedural outcomes are known to occur, so the models are frequently updated to accurately reflect these changes. As illustrated by Rogers et al, 2 inaccuracies and misclassification are likely if models developed for a certain year are applied to a patient population from a different year. This clearly constitutes a misuse of the STS surgical aortic valve replacement risk models. Another misuse of STS models is seen in the unfortunate tendency to use STS models to predict the risk of the TAVR procedure itself. There is widespread recognition that this yields inadequate estimates of TAVR risk.
3,4 Statistical risk models are designed to predict risk only for the population used to develop the models. To predict the risk of TAVR procedures, then, one should use risk models that have been developed solely for a TAVR population.
3,5
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Letters Prediction of adverse outcomes is clearly important, but especially in the TAVR population, there is a compelling need to also predict patient benefit. Even if there is a low chance of adverse events, the procedure should not be performed unless there is a reasonable probability of providing a tangible benefit. It may be possible to infer benefit by comparing preprocedure and postprocedure measurements of parameters that reflect physiologic status. Examples include grip strength and the 5-m walk test to measure frailty 9 and the Kansas City Cardiomyopathy Questionnaire 10 to quantitate symptoms of heart failure. If these metrics can be collected before and after the procedure, it then becomes possible to develop statistical models to predict preprocedure/postprocedure difference based on specific patient characteristics. If the preprocedure/ postprocedure difference is a reflection of "benefit," then developing predictive models of patient benefit should be straightforward. The ability to objectively predict patient benefit as well as patient risk will be critically important in the highrisk TAVR population. Statistical models to predict patient benefit are being developed by the Transcatheter Valve Therapy Registry and should provide a significant upgrade in our ability to evaluate candidates for the TAVR procedure. The unique aspects of TAVR have hastened the development of a new generation of predictive models. Reliance on models designed for other purposes should appropriately diminish as these newer, more procedure-specific models come on line as the standard for TAVR risk assessment. 
COMMENT & RESPONSE
Effect of Iron Levels on Women After Premature or Early-Onset Menopause
To the Editor In a systematic review, Muka et al 1 found a higher risk of cardiovascular disease mortality and a higher overall mortality in women who experience premature or early-onset menopause. We suggest that the substantial increase in serum ferritin levels at menopause signals a dramatic alteration in iron metabolism possibly associated with enhanced inflammatory responses. We ask the authors to consider that the observed and significant increase in risk of cardiovascular disease in women is associated with altered iron homeostasis and the possible increase in body iron stores after menstrual blood flow cessation.
2
The 1976 Framingham Study 3 provided groundbreaking evidence that menopause is associated with a highly significant, 2-fold increase in the incidence of heart disease. Cardiovascular protection diminished after surgical menopause, regardless of whether oophorectomy had been performed. Muka et al 1 emphasize the striking association between menopause and coronary risk without comment on the significant alteration in iron metabolism accompanying menstrual cessation. The hypothesis that increased cardiovascular disease following menopause results from oxidative stress catalyzed by excess iron accumulation was tested in the Veterans Affairs Cooperative Study Trial 410, The Iron and Atherosclerosis Study. Phlebotomy effects on clinical outcomes were tested in patients with peripheral arterial disease with iron store reduction, estimated by serum ferritin levels, to levels approaching 25 ng/mL, which occur in healthy menstruating women. 4 Data from this prospective study demonstrated that lower ferritin levels (eg, 76-78 ng/mL) predicted improved outcomes in younger men with peripheral arterial disease (later in smokers) on removal of an amount of iron represented by approximately a liter of blood. Lower ferritin levels strongly predicted improved clinical outcomes, regardless of randomization group, with a threshold for benefit below 76-78 ng/mL. We suggest that iron in catalytic form stimulates inflammatory responses and leukocyte activity and associates with elevation of interleukin 6 and other inflammatory biomarkers. We have reported direct associations 5 between elevated ferritin levels and inflammatory biomarkers, predominantly interleukin 6, and mortality.
